Perfusia Plus
Perfusia Plus by Thorne Research is a combination supplement in the Longevity & NAD+ category, featuring six distinct ingredients. It holds an N+ Score of 70, earning a 'C' grade, indicating a good quality product. The formula includes Vitamin C at 300mg and Folate at 552mcg, both of which are present at clinically studied dosages. However, the L-Arginine content is noted as underdosed relative to common clinical recommendations. With 100% label transparency, consumers can clearly see the dosages of all ingredients, including Green Tea Phytosome (200mg), R-Lipoic Acid (50mg), and Trans-Resveratrol (50mg). This product may be suitable for individuals interested in general longevity support and cardiovascular health, particularly those seeking specific dosages of Vitamin C and Folate.
About This Product
Perfusia Plus by Thorne Research is a longevity & nad+ supplement containing 6 active ingredients. It has earned an N+ Score of 70/100 (Grade C).
Notable clinical-dose ingredients include Folate, Vitamin C.
N+ Score Breakdown
Are key ingredients present at clinically effective doses based on research?
Does the product include all expected ingredients for its supplement category?
Are individual ingredient amounts clearly disclosed without proprietary blends?
Does the formula include a breadth of beneficial compounds from multiple pathways?
Strengths
- +Fully transparent label with individual ingredient amounts disclosed
- +Broad ingredient diversity exceeding category norms
- +2 ingredient(s) at clinical dose levels
Weaknesses
- −Missing several expected ingredients for its category
Ingredient Analysis (6 ingredients)
| Ingredient | Amount | Dose Adequacy |
|---|---|---|
| Folate | 552.000 mcg | Optimal |
| Vitamin C | 300.000 mg | Optimal |
| L-Arginine | 1.000 g | Under |
| R-Lipoic Acid | 50.000 mg | N/A |
| trans-Resveratrol | 50.000 mg | N/A |
| Green Tea Phytosome | 200.000 mg | N/A |
Clinical ranges based on NIH ODS Fact Sheets and peer-reviewed research. Status indicates whether the amount meets evidence-based thresholds.